ArticleAnalytical chemistry2025
Rational Modification of a Cross-Linker for Improved Flexible Protein Structure Modeling.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intrinsic N-Terminal Reactivity and Improved Analysis of DSSO-Carbamate and Carbamate-Based Cross-Linkers.Analytical chemistry · 2026Article
- Moonlighting Proteins: Unveiling Their Multifunctionality in Metabolic Regulation and Drug Discovery.Current drug metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chemical cross-linking/mass spectrometry (XL-MS) has emerged as a complementary tool for mapping interaction sites within protein networks as well as gaining moderate-resolution native structural insight with minimal interference. XL-MS technology mostly relies on chemoselective reactions (cross-linking) between protein residues and a linker. DSSO represents a versatile cross-linker for protein structure investigation and in-cell XL-MS. However, our assessment of its shelf life and batch purity revealed decomposition of DSSO in anhydrous solution via a retro-Michael reaction, which may reduce the active ingredient down to below 90%. To mitigate the occurrence of this degradative mechanism, we report the rational design and synthesis of DSSO-carbamate, which contains an inserted nitrogen atom in the DSSO backbone structure. This modification to DSSO yielded remarkably favorable stability against such decomposition, which translated to higher cross-link and monolink recovery when performing XL-MS on monomeric flexible proteins. Recently, XL-MS has been leveraged against AlphaFold2 and other protein structure prediction algorithms for improved prediction of flexible monomeric multiconformational proteins. To this end, we demonstrate that our novel cross-linker, termed DSSO-carbamate, generated more accurate protein structure predictions when combined with AlphaFold2, on account of its increased recovery of cross-links and monolinks, compared to DSSO. As such, DSSO-carbamate represents a useful addition to the XL-MS community, particularly for protein structure prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.